ArticleWorld journal of gastroenterology2004
Expression of survivin and its significance in colorectal cancer.
Article in World journal of gastroenterology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects.Molecular therapy. Oncology · 2026Article
- STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review).Biomedical reports · 2024Review
- Targeting survivin with Tanshinone IIA inhibits tumor growth and overcomes chemoresistance in colorectal cancer.Cell death discovery · 2023Article
- A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles.Gene therapy · 2019Article
- Interplay between Endoplasmic Reticular Stress and Survivin in Colonic Epithelial Cells.Cells · 2018Article
- Targeting PRPK Function Blocks Colon Cancer Metastasis.Molecular cancer therapeutics · 2018Article
- HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.Oncotarget · 2017Article
- Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice.Cancer letters · 2014Article
- Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.Medical oncology (Northwood, London, England) · 2013Article
- Article
- Expression of the survivin-2B splice variant related to the progression of colorectal carcinoma.Journal of the Korean Surgical Society · 2011Article
- Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector.Gene therapy · 2011Article
- Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR.World journal of gastroenterology · 2011Article
- Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance.Molecular and cellular biochemistry · 2010Article
- Change in Expression of Survivin Caused by Using Oxaliplatin in HCT116 Colon Cancer Cells.Journal of the Korean Society of Coloproctology · 2010Article
- Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer.International journal of colorectal disease · 2009Article
- Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.Digestive diseases and sciences · 2006Article
- Role of survivin and its splice variants in tumorigenesis.British journal of cancer · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the expression of survivin, a novel member of inhibitors of apoptosis protein (IAP) and its significance in colorectal carcinoma.
methodsSurvivin mRNA expression was evaluated by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in 52 colorectal carcinoma samples and 48 adjacent normal colorectal tissue samples. PCR product was sequenced to verify the desired result. Expressions of survivin protein, proliferating cell nuclear antigen labelling index (PI) and apoptotic index (AI) were detected immunohistochemically in 52 human colorectal carcinomas.
resultsThe expression of survivin mRNA was detected in a significantly greater proportion of colorectal carcinoma samples than in adjacent normal colorectal tissues (67.3% vs 25%; P<0.01). There was no relationship between survivin mRNA expression in colorectal carcinomas and sex, tumor size, histological types, lymphnode metastasis, distant metastasis and Dukes' stage. The PCR product shared 99% of homology with human counterparts. Survivin expression was observed immunohistochemically in 27 of 52 cases of colorectal carcinoma (51.9%). The AI was significantly lower in survivin positive group than in survivin negative group (0.67+/-0.18% vs 1.14+/-0.42%; P<0.001), while the PI was greater in survivin positive group than in survivin negative group (51+/-22% vs 27+/-18%, P<0.001).
conclusionSurvivin is a special tumor marker independent of histopathological characteristics. It may play an important role during human colorectal tumorigenesis by inhibiting apoptosis and accelerating proliferative activity of colorectal tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.